ascorbyl laurate | 16690-40-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ascorbyl laurate
• 英文别名: 5-(2-dodecanoyloxy-1-hydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one；dodecanoic acid 2-(3,4-dihydroxy-5-oxo-2,5-dihydro-furan-2-yl)-2-hydroxy-ethyl ester；Ascorbylmonolaurat；L-Ascorbic acid,6-dodecanoate；[2-(3,4-dihydroxy-5-oxo-2H-furan-2-yl)-2-hydroxyethyl] dodecanoate
• CAS: 16690-40-7；71623-60-4；140632-73-1
• 化学式: C₁₈H₃₀O₇
• 分子量: 358.432
• InChiKey: DWKSHXDVQRZSII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  月桂酸 、 异抗坏血酸 在 Staphylococcus xylosus lipase immobilized onto silica aerogel 作用下， 以 乙腈 、 叔丁醇 为溶剂， 反应 72.0h， 生成 ascorbyl laurate
  参考文献：
  名称：

  Lipophilization of Ascorbic Acid: A Monolayer Study and Biological and Antileishmanial Activities

  摘要：

  Ascorbyl lipophilic derivatives (Asc-C2 to Asc-C(18:1)) were synthesized in a good yield using lipase from Staphylococcus xylosus produced in our laboratory and immobilized onto silica aerogel. Results showed that esterification had little effect on radical-scavenging capacity of purified ascorbyl esters using DPPH assay in ethanol. However, long chain fatty acid esters displayed higher protection of target lipids from oxidation. Moreover, compared to ascorbic acid, synthesized derivatives exhibited an antibacterial effect. Furthermore, ascorbyl derivatives were evaluated, for the first time, for their antileishmanial effects against visceral (Leishmania infantum) and cutaneous parasites (Leishmania major). Among all the tested compounds, only Asc-C10, Asc-C12, and Asc-C(18:1) exhibited antileishmanial activities. The interaction of ascorbyl esters with a phospholipid monolayer showed that only medium and unsaturated long chain (Asc-C10 to Asc-C(18:1)) derivative esters were found to interact efficiently with mimetic membrane of leishmania. These properties would make ascorbyl derivatives good candidates to be used in cosmetic and pharmaceutical lipophilic formulations.

  DOI：

  10.1021/jf5029398

文献信息

• Cyclopentanone derivatives, method of synthesis and uses thereof
  申请人：Neuropharma S.A.

  公开号：EP1939192A1

  公开（公告）日：2008-07-02

  The present invention relates to cyclopentanone derivatives of formula (I), their method of synthesis and uses thereof. Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3β, GSK-3 β, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.

  本发明涉及公式（I）的环戊酮衍生物，其合成方法及用途。具体来说，所披露的化合物已被证明是糖原合成酶激酶3β（GSK-3β）的抑制剂，GSK-3β已知参与不同疾病和病况，如阿尔茨海默病或非胰岛素依赖型糖尿病。本发明还涉及包含这些化合物的药物组合物。此外，本发明旨在将这些化合物用于制造治疗和/或预防GSK-3介导的疾病或病况的药物。
• [EN] CYCLOPENTANONE DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF<br/>[FR] DÉRIVÉES DE CYCLOPENTANONE, LEUR MÉTHODE DE SYNTHÈSE ET LEURS UTILISATIONS
  申请人：NEUROPHARMA SA

  公开号：WO2008080988A2

  公开（公告）日：2008-07-10

  [EN] The present invention relates to cyclopentanone derivatives of formula (I), their method of synthesis and uses thereof. Also, the present invention relates to the use of cyclopentanone derivatives of formula (Ia). Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3ß, GSK-3 ß, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.
  [FR] L'invention porte sur des dérivées de cyclopentanone de formule (I), leur méthode de synthèse, et leurs utilisations. L'invention porte également sur l'utilisation des dérivées de cyclopentanone de formule (Ia). Concrètement, les composés de l'invention se sont avérés être des inhibiteurs de la kinase de la synthase du glycogène 3ß, GSK-3 ß, que l'on sait être impliquée dans différente maladie et états, dont la maladie d'Alzheimer ou le diabète sucré non insulinodépendant. L'invention porte également sur l'utilisation de ces composés dans la production de médicaments traitant et/ou prévenant des maladie et états médiées par la GSK-3.
• Lipophilization of Ascorbic Acid: A Monolayer Study and Biological and Antileishmanial Activities
  作者：Nadia Kharrat、Imen Aissa、Manel Sghaier、Mohamed Bouaziz、Mohamed Sellami、Dhafer Laouini、Youssef Gargouri

  DOI：10.1021/jf5029398

  日期：2014.9.17

  Ascorbyl lipophilic derivatives (Asc-C2 to Asc-C(18:1)) were synthesized in a good yield using lipase from Staphylococcus xylosus produced in our laboratory and immobilized onto silica aerogel. Results showed that esterification had little effect on radical-scavenging capacity of purified ascorbyl esters using DPPH assay in ethanol. However, long chain fatty acid esters displayed higher protection of target lipids from oxidation. Moreover, compared to ascorbic acid, synthesized derivatives exhibited an antibacterial effect. Furthermore, ascorbyl derivatives were evaluated, for the first time, for their antileishmanial effects against visceral (Leishmania infantum) and cutaneous parasites (Leishmania major). Among all the tested compounds, only Asc-C10, Asc-C12, and Asc-C(18:1) exhibited antileishmanial activities. The interaction of ascorbyl esters with a phospholipid monolayer showed that only medium and unsaturated long chain (Asc-C10 to Asc-C(18:1)) derivative esters were found to interact efficiently with mimetic membrane of leishmania. These properties would make ascorbyl derivatives good candidates to be used in cosmetic and pharmaceutical lipophilic formulations.